Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter

9 Mar 2021

Abstract excerpt

Abnormal DNA methylation patterns are thought to drive the pathobiology of high-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML). Sixteen years after their initial approval, the hypomethylating agents (HMAs), 5-azacytidine (AZA) and 5-aza-2′-deoxycytidine, remain the mainstay of treatment for HR-MDS and AML. However, a connection of the hypomethylating or additional effects of HMAs with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33768008
DOI: 10.3389/fonc.2021.650473

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the EpicenterPMID 33768008Read ↗

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulationSemantic proximity Read ↗

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read ↗

Immunological effects of hypomethylating agents.Semantic proximity Read ↗

The use of hypomethylating agents in the treatment of hematologic malignanciesSemantic proximity Read ↗

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studySemantic proximity Read ↗

DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AMLSemantic proximity Read ↗

Epigenetics in myeloid malignancies.Semantic proximity Read ↗

Targeting DNA MethylationSemantic proximity Read ↗

DNA Methylation–Targeted DrugsSemantic proximity Read ↗

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesSemantic proximity Read ↗

Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCsSemantic proximity Read ↗

The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.